Select publication to see the relevant sections.

Publication Date

    E.g., 2018-04-22
    E.g., 2018-04-22

Archive Search


255864 items
6:28 PM, Apr 20, 2018  |  BioCentury | Product Development

Redrawing the lines

Word that Merck & Co. Inc.’s Keytruda pembrolizumab had “won” the first-line lung cancer showdown with Bristol-Myers Squibb Co. at AACR spread quickly on Monday, but there was little discussion among investors and in the...
5:44 PM, Apr 20, 2018  |  BioCentury | Finance

Takeda’s math problem

A hefty net debt load of $18.8 billion for Shire plc (LSE:SHP; NASDAQ:SHPG) means Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) is having to pick its poison to reach a deal. The Japanese pharma is grappling with giving...
5:16 PM, Apr 20, 2018  |  BioCentury | Finance

Qiming’s cross-border connection

Qiming Venture Partners chose to focus its first ex-China fund on healthcare because the firm sees more interest in cross-border collaborations in life sciences than some of the other industries it invests in. Qiming unveiled...
5:01 PM, Apr 20, 2018  |  BioCentury | Finance

China’s early stage Panacea

Despite a recent wave of large funds investing in Chinese biotechs, new Chinese VC Panacea Venture believes a pair of funds totaling roughly $300 million is more than enough to pursue its early stage investing...
4:45 PM, Apr 20, 2018  |  BioCentury | Product Development

Lessons from the ECHO chamber

Lessons from the failure of ECHO-301 go beyond the prospects of combining IDO1 and PD-1 inhibition to treat cancer. The broader concern is for the gamut of Phase I/II trials testing PD-1 combinations, many of...
4:22 PM, Apr 20, 2018  |  BC Extra | Company News

Vertex to meet with NHS England to discuss Orkambi

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said it expects to meet with NHS England next week to discuss Orkambi ivacaftor/lumacaftor following its receipt of a letter from the U.K. Department of Health urging the company to proceed...
4:19 PM, Apr 20, 2018  |  BC Extra | Company News

Dicerna, Alnylam settle RNAi dispute

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) gained $1.82 (18%) to $12.01 Friday after the company said it had resolved all litigation with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) regarding RNAi-based treatments for primary hyperoxaluria, with neither company admitting wrongdoing. In...
3:56 PM, Apr 20, 2018  |  BioCentury | Emerging Company Profile

Clear for Landos

Landos Biopharma Inc. is developing a first-in-class LANCL2 agonist designed to provide improved convenience, efficacy and safety over standard-of-care therapies for inflammatory bowel disease (IBD), including moderate to severe Crohn’s disease (CD) and ulcerative colitis...
3:15 PM, Apr 20, 2018  |  BC Extra | Politics & Policy

Gottlieb unveils guidance for opioid dependence treatments

As part of an effort to address the opioid abuse epidemic, FDA released draft guidance for the development and clinical trial design of sustained-release depot buprenorphine products -- modified-release medication-assisted treatments (MATs) for injection or...
3:04 PM, Apr 20, 2018  |  BioCentury | Finance

Earnings on deck

Earnings on deck At least 17 profitable biotechs and pharmas are slated to report earnings this week. (A) During trading hours in London; premarket on U.S. exchange; (B) Fiscal 4Q; (C) 12-month EPS. CompanyDatePre/post mkt1Q18 EPS est1Q17...